antibody discover

From Difficult Targets to Drug-Grade Antibodies

We provide an end-to-end platform that expresses difficult targets and discovers high-quality antibodies against them. 

Targets—including soluble proteins and challenging membrane classes (GPCRs/ion channels/cytokines)—are produced in E. coli, yeast, and mammalian systems, with antigen formats tailored for discovery (purified protein, nanodiscs/nanovesicles, or cell-based display). 

Using AI-assisted design plus phage/yeast display and single-B-cell mining, we generate VHH/nanobody, scFv, and IgG leads, then triage for affinity, specificity, epitope, and developability. 

Functional assays confirm blocking/agonism; optional humanization, affinity maturation, and formatting (bispecific/multivalent/Fc-fusion, mRNA-ready ORFs) de-risk translation. 

All project results come with a comprehensive data package, or a customized set tailored to your needs.

Deliverables (typical):

• Antigen & antibody sequences/plasmids, purified proteins or mRNA-ready inserts
• Kinetics and specificity (SPR/BLI), epitope binning/mapping, stability/developability report
• Optional formatting to nanobody, IgG, bispecific, or LNP-targeting ligands, plus tech transfer